OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
The evolving landscape of COVID ‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC , the European research initiative on CLL
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1856-1868
Open Access | Times Cited: 14
Andrea Visentin, Thomas Chatzikonstantinou, Lydia Scarfò, et al.
American Journal of Hematology (2023) Vol. 98, Iss. 12, pp. 1856-1868
Open Access | Times Cited: 14
Showing 14 citing articles:
Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors
Stefano Molica, David Allsup
Cancers (2025) Vol. 17, Iss. 1, pp. 119-119
Open Access | Times Cited: 1
Stefano Molica, David Allsup
Cancers (2025) Vol. 17, Iss. 1, pp. 119-119
Open Access | Times Cited: 1
Long COVID in Children, Adults, and Vulnerable Populations: A Comprehensive Overview for an Integrated Approach
Valeria Calcaterra, Sara Zanelli, Andrea Foppiani, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 95-95
Open Access | Times Cited: 7
Valeria Calcaterra, Sara Zanelli, Andrea Foppiani, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 95-95
Open Access | Times Cited: 7
Awareness and Knowledge About Preventive Vaccinations Among Patients with Hematological Malignancies
Marta Morawska, Marta Masternak, Norbert Grząśko, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 284-284
Open Access
Marta Morawska, Marta Masternak, Norbert Grząśko, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 284-284
Open Access
Additional booster doses in patients with chronic lymphocytic leukemia induce humoral and cellular immune responses to SARS‐CoV‐2 similar to natural infection regardless ongoing treatments: A study by ERIC, the European Research Initiative on CLL
Alessandro Campanella, A Capasso, Silvia Heltai, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 745-750
Open Access | Times Cited: 3
Alessandro Campanella, A Capasso, Silvia Heltai, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 4, pp. 745-750
Open Access | Times Cited: 3
Chronic Lymphocytic Leukemia: Management of Adverse Events in the Era of Targeted Agents
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1996-1996
Open Access | Times Cited: 2
Andrea Galitzia, Monica Maccaferri, Francesca Romana Mauro, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 1996-1996
Open Access | Times Cited: 2
Innovative Combinations, Cellular Therapies and Bispecific Antibodies for Chronic Lymphocytic Leukemia: A Narrative Review
Andrea Visentin, Sara Frazzetto, Livio Trentin, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1290-1290
Open Access | Times Cited: 1
Andrea Visentin, Sara Frazzetto, Livio Trentin, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1290-1290
Open Access | Times Cited: 1
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
Κώστας Σταματόπουλος, Šárka Pavlová, Othman Al‐Sawaf, et al.
HemaSphere (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 1
Κώστας Σταματόπουλος, Šárka Pavlová, Othman Al‐Sawaf, et al.
HemaSphere (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 1
Outcomes of COVID-19 infection in patients with chronic lymphocytic leukemia: a systematic review and meta-analysis
Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Farid Jahanshahlou, et al.
Revista da Associação Médica Brasileira (2024) Vol. 70, Iss. 8
Open Access | Times Cited: 1
Mohammad Amin Akbarzadeh, Yosra Vaez-Gharamaleki, Farid Jahanshahlou, et al.
Revista da Associação Médica Brasileira (2024) Vol. 70, Iss. 8
Open Access | Times Cited: 1
The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia
Shenmiao Yang, Rong Wei, Hongxia Shi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Shenmiao Yang, Rong Wei, Hongxia Shi, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Severe infections in patients with chronic lymphocytic leukemia included in trials investigating BTK and BCL2 inhibitors
Francesca Romana Mauro, Anna Maria Frustaci, Andrea Visentin, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104408-104408
Closed Access
Francesca Romana Mauro, Anna Maria Frustaci, Andrea Visentin, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 201, pp. 104408-104408
Closed Access
Management of infections for patient treated with ibrutinib in clinical practice
Claudia Baratè, Ilaria Scortechini, Sara Ciofini, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Claudia Baratè, Ilaria Scortechini, Sara Ciofini, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
COVID-19 in patients with Chronic Lymphocytic Leukemia treated with venetoclax: what is the role of anti-CD20 antibody?
Francesco Autore, Andrea Visentin, Marina Deodato, et al.
Blood Advances (2024) Vol. 9, Iss. 1, pp. 162-165
Open Access
Francesco Autore, Andrea Visentin, Marina Deodato, et al.
Blood Advances (2024) Vol. 9, Iss. 1, pp. 162-165
Open Access
Editorial: Covid-19 therapies in patients with hematologic malignancies
Andrea Visentin, Massimo Gentile
Frontiers in Oncology (2024) Vol. 14
Open Access
Andrea Visentin, Massimo Gentile
Frontiers in Oncology (2024) Vol. 14
Open Access
